SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Nomura Stock Upgraded to Buy by BofA as Stronger ROE and Earnings Growth Boost Outlook 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
SpaceX, Charter Communications Explore Mobile Partnership to Expand Starlink Wireless Service 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Johns Hopkins University Lays Off 110 Employees as Federal Research Funding Declines 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Apple Supplier Stocks Slide as Samsung, SK Hynix Lead Selloff After Apple Price Hikes 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
China Eastern Orders 25 Airbus A330neo Jets in $9.35 Billion Deal to Boost International Expansion 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
US Judge Seeks Explanation for DOJ’s Decision to Drop Gautam Adani Bribery Case 
PARSIPPANY, N.J., May 10, 2017 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the Bank of America Merrill Lynch 2017 Healthcare Conference at 8:00 AM PT on Wednesday, May 17, 2017 in Las Vegas.
A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the presentation date.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Company Contact: Pacira Pharmaceuticals, Inc. Susan Mesco (973) 451-4030 [email protected]
